Xenon
As of the edition of 20 October 2026, Xenon is a small molecule: marketed, first approved in 1982 (US); no US protection of its own is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Xeneisol
- First approved
- 1 January 1982 (US)
- Approvals on record
- 16 in 1 region
- Holder of the most recent approval
- Polarean; 7 holders in all
- Registered trials
- 37, 8 stopped early
- Disease areas
- Lungs and airways; Heart and blood vessels; Mental health; Nervous system; Digestive system; Cancer
US protection
No US protection of its own is listed.
The FDA registers list no drug-substance patent or exclusivity of its own that counts for this drug.
Polarean holds a later exclusivity on its own new formulation or combination product, ending 2027; it does not protect the original drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 2 | 2 | 0 |
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 14 | 4 | 7 | 3 |
| Phase 3 | 9 | 6 | 0 | 2 |
| Phase 4 | 5 | 4 | 0 | 1 |
| All trials | 37 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Lantheus Medical Imaging | Acquired holder | 2008 to now |
| Curium | Acquired holder | 2019 to now |
| Polarean | Later holder | 2022 to now |
| Shine Spect | Acquired holder | 2026 to now |
| Byk-Mallinckrodt CIL | Later holder | |
| GE Healthcare | Applicant | |
| General Electric | Later holder |